The first-in-human trial results showed the drug was well tolerated across all single ascending dose cohorts, with an estimated half-life supporting infrequent dosing intervals.
### Phase 1 Trial Design and Safety Findings
The ongoing clinical evaluation, identified as trial NCT07317544, is a randomized, double-blind, placebo-controlled study assessing ABS-201 in healthy adult volunteers with and without androgenetic alopecia. According to data released by Absci Corporation, the initial single ascending dose portion enrolled 32 participants across four cohorts receiving intravenous doses of 150 mg, 450 mg, 900 mg, or 1800 mg. Blinded safety data evaluated by the trial’s Safety Review Committee as of the June 8, 2026, cutoff indicated that treatment-emergent adverse events were predominantly mild. No serious adverse events occurred during the single ascending dose evaluation. Five participants reported treatment-related adverse events, all of which were mild in severity. The most frequently observed side effect across the cohorts was headache, occurring in four participants, including one moderate instance in the 900 mg cohort that was assessed as unlikely related to the study treatment.
### Pharmacokinetics and Dosing Potential
Pharmacokinetic evaluations across all four single ascending dose cohorts demonstrated an estimated drug half-life of at least 65 days. According to Absci Corporation, this extended half-life supports a targeted dosing schedule of two or three injections over a six-month period. Initial immunogenicity assessments indicated that anti-drug antibodies did not exert an apparent impact on the pharmacokinetics of ABS-201 during the single ascending dose phase.
### Next Steps in Clinical Development
Following the Safety Review Committee’s evaluation of the single ascending dose data, the trial advanced into a subcutaneous multiple ascending dose portion involving participants with androgenetic alopecia. Absci Corporation’s Chief Medical Officer, Ransi Somaratne, MD, stated that the company is encouraged by the emerging safety, pharmacokinetic, and immunogenicity profile and looks forward to characterizing the clinical profile further in the multiple ascending dose portion of the HEADLINE trial. The company anticipates interim proof-of-concept data for the trial in the second half of 2026, with full proof-of-concept results expected in early 2027. Additionally, Absci Corporation plans to initiate a Phase 2 clinical trial for endometriosis later in 2026.